Abstract:
Electrochemotherapy is a local non-thermal treatment for cancer ablation. Currently, many studies and case report have investigated the differences in effectiveness of electrochemotherapy with respect to tumor type, chemotherapeutic drug, and route of drug administration. ESOPE trial validated standard operating procedures [SOP] for ECT using the Cliniporator device and demonstrated that ECT is a simple, highly efficacious, and cost-effective treatment of cutaneous and subcutaneous nodules from different primary tumors for cutaneous or superficial lesions. This presentation has the purpose to summarize current knowledge about clinical effectiveness of electrochemotherapy and future prospects regarding its use on pancreatic cancer and liver metastasis.
Biography:
Dr Izzo is Director and Chief of the Hepatobiliary and Pancreatic Unit, within the Department of Surgical Oncology at the National Cancer Institute of Naples. His clinical practice and research focuses on new surgical oncology treatments and he has been a pioneer in designing improved techniques for surgical removal of hepatic tumours and direct tumour injection therapies. Additionally, Dr Izzo is Principal Investigator of a number of national and international protocols in this field and has authored or co-authored more than 220 publications and 18 book chapters relating to the treatment of patients with HPB tumours. Total Impact Factor: 638,003 ; H-INDEX: 35; Sum of the times citated: 7.017; Database utilized: SCOPUS for H-Index and Bibliosan for IF.
